XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity
 6 Months Ended
Jul. 31, 2019
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
The fair value of the Company's stock options and ESPP shares was estimated on the date of grant and the first day of the ESPP purchase period, respectively, using the Black-Scholes option pricing model. The weighted-average fair value per share for stock options grants was $38.97 and $40.69 in the three and six months ended July 31, 2019, respectively, compared to $32.35 and $28.69 in the three and six months ended July 31, 2018, respectively. The weighted-average fair value per share for ESPP shares was $38.88 in the three months ended July 31, 2019 compared to $32.26 in the three months ended July 31, 2018.
Stock option activity for the six months ended July 31, 2019 is as follows:
 
Options Outstanding
 
Outstanding
Stock
Options
(in millions)
 
Weighted-
Average
Exercise Price
 
Aggregate
Intrinsic Value (in millions)
Balance as of January 31, 2019
26

 
$
74.15

 
 
Options granted under all plans
6

 
160.40

 
 
Exercised
(3
)
 
55.34

 
 
Canceled
(1
)
 
108.14

 
 
Balance as of July 31, 2019
28

 
$
94.60

 
$
1,745

Vested or expected to vest
26

 
$
91.53

 
$
1,699

Exercisable as of July 31, 2019
13

 
$
65.76

 
$
1,236


The following table summarizes information about stock options outstanding as of July 31, 2019:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise
Prices
 
Number
Outstanding
(in millions)
 
Weighted-
Average
Remaining
Contractual Life
(Years)
 
Weighted-
Average
Exercise
Price
 
Number of
Shares
(in millions)
 
Weighted-
Average
Exercise
Price
$0.27 to $52.30
 
5

 
4.2
 
$
30.34

 
4

 
$
33.10

$54.36 to $75.57
 
7

 
3.6
 
67.79

 
5

 
65.73

$76.48 to $113.00
 
4

 
3.7
 
84.54

 
3

 
82.74

$118.04
 
5

 
5.6
 
118.04

 
1

 
118.04

$122.03 to $158.76
 
1

 
6.3
 
141.75

 
0

 
0.00

$161.50
 
6

 
6.6
 
161.50

 
0

 
0.00

 
 
28

 
4.8
 
$
94.60

 
13

 
$
65.76


Restricted stock activity for the six months ended July 31, 2019 is as follows:
 
Restricted Stock Outstanding
 
Outstanding
(in millions)
 
Weighted Average Grant Date Fair Value
 
Aggregate
Intrinsic
Value (in millions)
Balance as of January 31, 2019
21

 
$
103.33

 
 
Granted - restricted stock units and awards
9

 
160.75

 
 
Granted - performance-based stock units
1

 
161.50

 
 
Canceled
(1
)
 
108.35

 
 
Vested and converted to shares
(6
)
 
99.70

 
 
Balance as of July 31, 2019
24

 
$
126.53

 
$
3,687

Expected to vest
20

 
 
 
$
3,148


During the six months ended July 31, 2019, the Company recognized stock-based expense related to its equity plans for employees and non-employee directors of $731 million. As of July 31, 2019, the aggregate stock compensation remaining to be amortized to costs and expenses was approximately $3.4 billion. The Company will amortize this stock compensation balance as follows: $778 million during the remaining six months of fiscal 2020; $1.1 billion during fiscal 2021; $875 million during fiscal 2022; $525 million during fiscal 2023 and $82 million during fiscal 2024. The expected amortization reflects only
outstanding stock awards as of July 31, 2019 and assumes no forfeiture activity. The aggregate stock compensation remaining to be amortized to costs and expenses will be recognized over a remaining weighted average period of two years.
Shares reserved and available for future issuance as of July 31, 2019 and January 31, 2019 were 133 million shares and 115 million shares, respectively.